Objectives: Nuclear expression of the PAX5 protein is widely utilized as a diagnostic marker for B-cell lymphoid malignancies. However, cytoplasmic PAX5 (cPAX5) expression has not been evaluated. Recently we encountered granular cPAX5 staining in rectal carcinoid (grade 1 neuroendocrine tumor [NET] by 2010 World Health Organization) in the absence of nuclear staining. We investigated the specificity of this pattern for rectal carcinoid tumors by evaluating additional NETs and neuroendocrine carcinomas (NECs) from the gastrointestinal (GI) and pancreatobiliary (PB) tracts, and liver. Conclusion: cPAX5 immunoreactivity appears fairly specific for rectal NET, and thus may be utilized as a diagnostic and prognostic marker for this entity. The mechanism of the subcellular localization of PAX5 expression warrants further investigation. Given the predominance of cPAX5 in low-grade NET of the rectum, it may be a result of cross-reactivity between the PAX5 antibody and pancreatic polypeptide in L-cell type NET, which is the most common subtype with indolent behavior in the rectum.
Objectives: Nuclear expression of the PAX5 protein is widely utilized as a diagnostic marker for B-cell lymphoid malignancies. However, cytoplasmic PAX5 (cPAX5) expression has not been evaluated. Recently we encountered granular cPAX5 staining in rectal carcinoid (grade 1 neuroendocrine tumor [NET] by 2010 World Health Organization) in the absence of nuclear staining. We investigated the specificity of this pattern for rectal carcinoid tumors by evaluating additional NETs and neuroendocrine carcinomas (NECs) from the gastrointestinal (GI) and pancreatobiliary (PB) tracts, and liver. Methods: Archived pathology materials (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) from 86 NETs and 40 NECs were reviewed. Representative tumor sections were subject to immunohistochemical stain for PAX5 (Ventana pre-dilute clone SP34, monoclonal) antibody. The extent [focal (<10%), patchy (10%-50%), diffuse (>50%)] and intensity [1+ to 3+] of cPAX5 within the tumor was evaluated. Results: cPAX5 was observed in 94% (17/18) rectal NETs and 14% (2/14) pancreatic NETs. Three of 13 (23%) metastatic NET to the liver also showed cPAX5 staining. The intensity was 2+, except for four cases with 1+ staining. Conclusion: cPAX5 immunoreactivity appears fairly specific for rectal NET, and thus may be utilized as a diagnostic and prognostic marker for this entity. The mechanism of the subcellular localization of PAX5 expression warrants further investigation. Given the predominance of cPAX5 in low-grade NET of the rectum, it may be a result of cross-reactivity between the PAX5 antibody and pancreatic polypeptide in L-cell type NET, which is the most common subtype with indolent behavior in the rectum.
Differing Plasma and Serum Lactate Dehydrogenase Concentrations
Crystal Bockoven, MD, Mary Granato, MT(ASCP), Robert Benirschke, PhD, Hong Lee, PhD; NorthShore University Health System Background: Serum lactate dehydrogenase (LDH) concentrations have been used in investigation of diseases involving many organs, including the heart, liver, kidney, muscle, and blood. It is also used to monitor tumor burden. LDH is an intracellular enzyme and can be released during cellular damage. When our hospital switched the preferred sample type for LDH from serum to plasma, an increased number of samples had results above the reference range, and clinicians were questioning the reason. Objective: To evaluate if there is a difference in LDH concentrations in plasma versus serum samples in our patient population. To evaluate if there is a significant difference between the hemolytic indices in plasma versus serum samples. Methods: LDH was measured in 110 paired plasma and serum samples over a two-week period. Hemolytic indices were performed on each sample. The samples were randomly selected, without knowing patient diagnosis. These paired samples were drawn in a single setting and stored under the same conditions. Manufacturer's instructions indicated that plasma must be free from hemolysis and cells. For the last 14 paired samples, a cell count was done to evaluate if there were cells present in the sample. Deming regression fit and Bland-Altman difference plots were used to analyze the data. Results: Plasma LDH was on average 22% higher than serum LDH. There was no difference in the hemolytic index between plasma and serum samples. In the last 14 samples, the cell counts revealed increased numbers of platelets in the plasma samples compared to serum samples.
Conclusion:
We proposed switching back to using serum for LDH testing, as there was an unpredictable increase in plasma LDH concentrations. These increases in LDH levels may be linked to the platelets that were still present in the sample and that may lyse or become activated with storage at refrigerated temperature.
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A Year of DFS70 ANA Testing in a Community Hospital Laboratory
Sara Carter, MT(ASCP) SM,SI,QIHC, John Carter, MD, FASCP, FCAP, M. John Spalding, MD, FASCP, FCAP; Lexington Medical Center Introduction: A dense fine-speckled (DFS) pattern is a very common antinuclear antibody (ANA) pattern in our community hospital patient population, often present in very high titers and often associated with anti-DFS70 extractable nuclear antigen (ENA) specificity. The IIF pattern on
